Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Colorcon
McKesson
Johnson and Johnson
Merck

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

SEREVENT Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Serevent patents expire, and what generic alternatives are available?

Serevent is a drug marketed by Glaxosmithkline and is included in two NDAs.

The generic ingredient in SEREVENT is salmeterol xinafoate. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the salmeterol xinafoate profile page.

Drug patent expirations by year for SEREVENT
Drug Prices for SEREVENT

See drug prices for SEREVENT

Recent Clinical Trials for SEREVENT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Università degli Studi di FerraraPhase 4
Pearl Therapeutics, Inc.Phase 2
Intech Biopharm Ltd.Phase 1

See all SEREVENT clinical trials

Recent Litigation for SEREVENT

Identify potential future generic entrants

District Court Litigation
Case NameDate
Meda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc.2015-09-08
Ted Miller Dairy LLC2010-02-17

See all SEREVENT litigation

Pharmacology for SEREVENT
Synonyms for SEREVENT
( inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; GR 33343X
(+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol
(+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol
1-hydroxy-2-naphthoic acid;4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]-2-methylol-phenol
1,3-Benzenedimethanol, 4-hydroxy-.alpha.1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl-, (+-)-
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-
1,3-Benzenedimethanol, 4-hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-
1,3-Benzenedimethanol,4-hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]methyl]-
136112-01-1
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol
2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
2-hydroxymethyl-4-{1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl}phenol
365S504
4-(1-hydroxy-2-((6-(4-phenylbutoxy)hexyl)amino)ethyl)-2-(hydroxymethyl)phenol
4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol
5-[2-[6-(4-Phenylbutoxy)hexylamino]-1-hydroxyethyl]-2-hydroxybenzenemethanol
89365-50-4
94749-08-3 (xinafoate)
AB00513972
AB00513972-07
AC1L1JPX
ACM136112011
ACMC-1C1VM
Aeromax
AK173141
AKOS005561914
AN-6615
API0004131
Astmerole
BC202639
BCP04199
BDBM25771
BPBio1_001002
BRD-A01320529-001-05-9
BSPBio_000910
C-21992
C07241
CAS-89365-50-4
CC-34358
CCG-101194
CCG-205176
CHEBI:64064
CHEMBL1263
CPD000466295
CS-2815
CS0057
CTK4C0163
D05792
DB00938
DSSTox_CID_3571
DSSTox_GSID_23571
DSSTox_RID_77087
DTXSID6023571
Fluticasonepropiponate
FT-0600807
FT-0674509
GIIZNNXWQWCKIB-UHFFFAOYSA-N
GR 33343 X
GR 33343X
GR-33343-X
GR-33343X
GTPL559
HMS2052H13
HMS2090E17
HMS2097N12
HMS3268K19
HMS3394H13
HMS3714N12
HSDB 7315
HY-14302
K590
KB-146003
KS-00000L6B
L000532
Lopac0_001100
LS-29869
MLS000759000
MLS001424322
MolPort-005-933-084
MRF-0000468
NC00444
NCGC00015938-03
NCGC00025247-01
NCGC00025247-02
Prestwick3_000945
Q-101428
S 2692
SALMATEROL
Salmeterol
Salmeterol (USAN/INN)
Salmeterol [USAN:BAN:INN]
Salmeterol [USAN:INN:BAN]
Salmeterol Fluticasone Propionate Mixture
Salmeterol Impurity H (Xinafoate Adduct Impurity)
SalMeterol Xinafoate Adduct IMpurity
Salmeterolum
Salmeterolum [Latin]
SAM001247096
SC-23297
SC-67460
SCHEMBL4767
SMR000466295
SN408D
SR-01000076139
SR-01000076139-2
SR-01000076139-6
STK629186
TL80090037
Tox21_113584

US Patents and Regulatory Information for SEREVENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate AEROSOL, METERED;INHALATION 020236-001 Feb 4, 1994 DISCN No No   Start Trial   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for SEREVENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
Glaxosmithkline SEREVENT salmeterol xinafoate POWDER;INHALATION 020692-001 Sep 19, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
Mallinckrodt
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.